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over different combinations of patient weight and surface area.
RESULTS: Savings of €3,404 per course per patient were shown;
potentially saving the Italian health care system €7.67 million per
year. This assumes that of the 2,252 third-line patients, 57%
receive panitumumab and 43% receive Active Supportive Care in
Year 1 based on the prevalence of the wild-type K-RAS mutation,
compared with 100% receiving cetuximab. CONCLUSIONS:
Results indicate that substantial savings are associated with pani-
tumumab therapy over cetuximab therapy at national and per-
patient levels.
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OBJECTIVES: This study evaluates the cost-effectiveness and
the budget impact of ixabepilone, a new microtubule stabilizer
for treatment of breast cancer, as part of the Formulary Man-
agement System at a major tertiary cancer center in the United
States. METHODS: A decision analytical model was developed
to estimate the incremental cost-effectiveness of ixabepilone for
breast cancer, in patients who failed treatment with anthracy-
cline and taxane. The model compared two strategies: combi-
nation therapy of ixabepilone with capecitabine compared to
capecitabine alone. The outcome of interest was progression
free life year (PFLY), based on published literature and clinical
use estimates. Direct institutional medical costs for a one-year
time period were utilized. One-way and two-way sensitivity
analyses on the probabilities of disease progression were con-
ducted. In addition, a budget impact analysis was also con-
ducted for adding ixabepilone in the Formulary. RESULTS:
Based on outcome estimates from literature and the application
of the institutional costs, the cost per PFLY saved for ixabepi-
lone for treatment of advanced breast cancer was $318,404.
One-way sensitivity analysis on the efﬁcacy probability (0–1.0)
of the combination therapy indicated that ixabepilone’s cost-
effectiveness ratios ranged from $205,000 to $1,190,000 per
PFLY saved. Two-way sensitivity analysis with a willingness-to-
pay threshold of $250,000 indicated that the majority of the
time monotherapy is the more cost-effective option. Only if
the probability of response to the combination is >30% and the
probability of response to the monotherapy is <33%, does the
combination therapy become more cost-effective. The budget
impact model showed that the institution will utilize about
$7.39 million worth of ixabepilone annually based on acquisi-
tion costs. CONCLUSIONS: Ixabepilone appears to be less
cost-effective than other neoplastic agents for treatment of
breast cancer. Future economic analyses will be conducted to
determine how closely the current economic model predicts
actual utilization and cost-effectiveness at the institution.
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OBJECTIVES: The purpose of this study was to analyse the
disease-related costs as well as the side effect hand-foot syndrome
(HFS) in oncologic patients receiving capecitabine. HFS is a dose
and therapy limiting toxicity which is classiﬁed into severity
grades 1 to 3. METHODS: Between April 2006 and August 2007
an observational study was conducted in Bonn, Germany on two
oncologic outpatient wards and three oncologic practices. Breast
and colorectal cancer patients starting oral chemotherapy with
capecitabine were included and followed for six months. They
rated their HFS at the end of each capecitabine cycle. The HFS
grades were transformed into utility weights obtained from an
earlier study in our group. From the perspective of the German
statutory health insurance the direct disease-related costs (out-
patient costs for pharmacotherapy, oncologist visits, diagnostics
and inpatient costs) were assessed in a microcosting approach
and referred to 2008. RESULTS: Thirty patients (16 breast, 14
colorectal cancer) were included. Their mean HFS severity grade
was 1.1 (SD 0.7, median 1.0, range 0 to 2.75) corresponding to
a mean utility weight of 0.88 (SD 0.14, median 0.92, range 1.00
to 0.44). Seven patients showed a HFS grade 3 (utility weight:
0.34) at least in one capecitabine cycle. On average €18,305
(80.4% outpatient, 19.6% inpatient) were calculated per breast
cancer patient and €25,863 (71.2% outpatient, 28.8% inpatient)
per colorectal cancer patient. Concerning the outpatient treat-
ment, costs for pharmacotherapy represented the highest matter
of expense (96.0% breast, 95.0% colorectal cancer). CONCLU-
SIONS: In most patients HFS occurred in moderate severity.
Nevertheless, 7 patients experienced HFS grade 3 affecting
quality of life. Strategies to prevent this toxicity need to be
developed. Especially costs for pharmacotherapy represent a
cost-driving factor in this patient group indicating a need for
strategies to optimize cost structure while containing or improv-
ing quality of treatment.
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OBJECTIVES: Panitumumab is the ﬁrst fully human anti-EGFR
monoclonal antibody to be approved as monotherapy for
patients with wild type (wt) KRAS mCRC after failure of
ﬂuoropyrimidine-, oxaliplatin-, and irinotecan-containing che-
motherapy regimens. This novel treatment approach is the begin-
ning of a new era of personalised treatment whereby KRAS
status is evaluated and only patients who are likely to respond
(wt KRAS) receive treatment. The objective of this study was to
evaluate the overall budget impact (BI) of the use of panitu-
mumab versus testing KRAS and treating patients with wt KRAS
in Greece. METHODS: To consider overall costs associated with
panitumumab treatment versus testing KRAS status and treating
only wt KRAS patients with panitumumab, a decision analytic
model was developed to evaluate BI. Primary drug costs, con-
comitant medications, infusion costs, radiation therapy, clinic
visits, and hospitalisations were included in treatment costs. An
expert panel was employed to map mCRC patient ﬂow as a local
cancer registry was not available. In this analysis, cost calcula-
tions for the public and private sectors were conducted sepa-
rately. RESULTS: Out of 470 potentially eligible patients for
panitumumab monotherapy, the decision analytic model targets
268 (57%) patients with wt KRAS, according to indication.
Potential total cost of receiving panitumumab without taking
KRAS status into consideration was €8.4 million in the public
sector, while total cost including KRAS testing to all patients but
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treating only the wt KRAS patients with panitumumab was €4.9
million, resulting in 41.7% savings. Total cost ﬁgures for the
private sector were €8.7 million and €5 million respectively,
resulting in 42.5% savings. CONCLUSIONS: By identifying the
wt KRAS patients who are most likely to respond to treatment,
panitumumab improves treatment outcomes and reduces unnec-
essary exposure to therapy, resulting in overall budget savings.
Patient-level clinical beneﬁts derived by panitumumab may lead
to improvements in health outcomes and rational allocation of
health care resources in Greece.
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OBJECTIVES: A molecular assay (GeneSearch™ Breast Lymph
Node (BLN) Assay, Veridex, LLC), CE marked and approved by
the FDA, has been in clinical use at our institution for over 18
months to intra-operatively detect metastases 30.2 mm in the
sentinel lymph nodes (SLNs) of breast cancer patients. After a
small validation study (N = 78, sensitivity = 92.3%, speciﬁc-
ity = 96.9%) the assay was adopted as the only intra-operative
SLN test used at the Institut Jules Bordet. This is the ﬁrst evalu-
ation of the cost savings generated by the use of this BLN assay.
METHODS: An economic evaluation was conducted in the ﬁrst
300 patients in whom this BLN assay was used intra-operatively.
The BLN assay results are used to make intra-operative decisions
for axillary lymph node dissections (ALND) during the same
surgery. We assessed the pathology, surgery & anesthesia, phar-
macy, post-hospitalization, general, and total costs associated
with patients having either: Surgery A = a lumpectomy +
SLN + secondary ALND versus having: Surgery B = a
lumpectomy + BLN + ALND. RESULTS: The total costs per
patient for Surgery A was €3120, while for Surgery B it was
€2210. Therefore, a difference of €910, were saved per patient
when using the BLN assay, which represents a 29% cost savings.
Since 58 patients avoided having a second surgery, the total cost
savings accrued by the institution for the Belgian social security
system as a result of using the BLN assay in this ﬁrst cohort of
300 patients, was €52,780. CONCLUSIONS: The BLN assay
was proved to be beneﬁcial not only for our patients by reducing
the need of second surgeries, it has also been demonstrated to be
cost saving for the Belgian social security system. Its use at the
Institut Jules Bordet in the ﬁrst cohort of 300 patients has
resulted in a cost savings of €52,780.
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OBJECTIVES: To estimate the cost effectiveness of the addition
of cetuximab to chemotherapy in 1st-line metastatic colorectal
cancer (mCRC) from the UK NHS perspective. METHODS:
Cetuximab is licensed for the treatment of mCRC in combination
with chemotherapy (FOLFIRI and FOLFOX) in patients with
wildtype KRAS and EGFR expressing tumours. A Markov model
was developed to simulate disease progression, survival and
potential for curative surgery. Progression-free survival data were
extrapolated in the basecase analysis, utilising different paramet-
ric models. The potential for curative-intent liver surgery is esti-
mated from Folprecht et al. [1] which demonstrated correlation
between response rates to chemotherapy and resection rates.
Base case resection rates (active/comparator) of 22%/12%
(FOLFIRI) and 15%/7% (FOLFOX) were assumed using this
correlation. The long-term beneﬁts of surgery were estimated
from Adam et al [2]. Treatment in specialised centres may lead to
vial sharing and higher resection rates (55%/35% and 42%/26%
respectively), these assumptions are tested in sensitivity analysis.
The 1st line utility value (0.77) in the model was derived from
EQ5D data collected in the FOLFIRI trial. RESULTS: In the
basecase the addition of cetuximab to FOLFIRI/FOLFOX
resulted in: incremental life years gained of 0.358 and 0.413;
additional QALYs of 0.281 and 0.320; incremental cost effec-
tiveness ratios (ICERs) of £69,287 and £63,245 per QALY and
ICERs in specialised centres of £34,646 and £40,529. The ICER
is mainly driven by the number of patients becoming resectable
the acquisition cost of cetuximab, and parameterisation of the
progression-free survival curves. CONCLUSIONS: The analysis
demonstrates the role of cetuximab in enabling curative surgery
which drives the cost-effectiveness. When assessing a highly
selected group of patients within a subset with wild-type KRAS,
the ICERs are close to UK willingness to pay acceptance thresh-
olds. [1] Folprecht G, Grothey A, Alberts S et al, Neoadjuvant
treatment of unresectable colorectal liver metastases: correlation
between tumour response and resection rates. Ann Oncol
2005;16:1311–9; [2] Adam R et al, Rescue Surgery for Unresec-
table Colorectal Liver Metastases Downstaged by Chemo-
therapy. A Model to Predict Long-term Survival. Ann Surgery
2004;240.
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OBJECTIVES: To evaluate the cost-effectiveness of standard che-
motherapy plus adjuvant trastuzumab treatment for one year
compared to standard chemotherapy in patients with early breast
cancer in Saudi Arabia. METHODS: A Markov model was
adapted to estimate the costs and clinical outcomes (quality-
adjusted life-years (QALYs) and life expectancy) associated with
the progression of early breast cancer over patients’ lifetimes.
Patients transitioned through ﬁve health states according to
probabilities reﬂecting the rates of disease progression observed
in the HERA (HERceptin Adjuvant) trial. Total health care
resource costs and utilization were estimated for each health state
using values derived from a Saudi Arabian-speciﬁc survey. The
analysis was done from the perspectives of the health care pro-
vider and society. The mean starting treatment age was assumed
to be 30 years old, reﬂecting local demographics. Costs and
outcomes were discounted at 3.5% per annum. Sensitivity analy-
ses were performed. RESULTS: One-year adjuvant treatment
with trastuzumab was estimated to increase life expectancy by
2.4 (4.9 undiscounted) years and quality-adjusted life years by
2.2 (4.3 undiscounted) QALYs, compared to standard chemo-
therapy. Over a patient’s lifetime, total direct medical costs,
including indirect costs (attributed to travel and time off work for
patients and care-givers), were projected to increase by approxi-
mately SR48,452 (US$12,903) compared to chemotherapy
alone. Treatment with trastuzumab was estimated to partially
offset mean event and state costs compared to chemotherapy
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